Interdialytic blood pressure variability and the risk of stroke in maintenance hemodialysis patients

Yue Cheng, MD\textsuperscript{a}, Yunning Li, PhD\textsuperscript{b,c,}\textsuperscript{∗}, Fan Zhang, MD\textsuperscript{a}, Jun Zhu, MD\textsuperscript{a}, Tao Wang, MD\textsuperscript{a,}, Meng Wei, MD\textsuperscript{a}, Liwen Mo, MD\textsuperscript{a}, Yi Li, MD\textsuperscript{a}

Abstract
Studies on nondialysis populations have linked visit-to-visit blood pressure (BP) variability (BPV) to cerebrovascular events and mortality. In view of the high prevalence of hypertension in hemodialysis patients, the predictive values of numerous factors for stroke, especially visit-to-visit BPV, were evaluated in this prospective cohort study.

A total of 151 patients were enrolled in this study. The demographic features and various laboratory parameters were analyzed. At each routine hemodialysis visit, the predialysis, intradialysis, and post-dialysis BP measurements were systematically performed. We defined BPV using 4 metrics: standard deviation of the BP, coefficient of variation, average real variability (ARV), and variability independent of mean (VIM). Differences in the predialysis BPs from one treatment to the next (ie, interdialytic variability) and differences in the BPs from predialysis to post-dialysis (ie, intradialytic variability) were both studied in this work.

Twenty-one patients developed stroke and 25 patients died. The multivariate Cox proportional hazards regression model revealed a significant relationship between stroke and the interdialytic BPV (both predialysis systolic BP variability and predialysis diastolic BP variability) and low-density lipoprotein-cholesterol (LDL-C).

Our results indicate that a high interdialytic BPV is associated with an increased risk for stroke that is independent of several factors, including age, sex, antihypertensive medication use, and mean BP over time. There is potential that the optimal treatment goal for hemodialysis patients may be to reduce the interdialytic BPV rather than either the mean BP or the intradialytic BPV.

Abbreviations: ADBP = average diastolic blood pressure, ARV = average real variability, ASBP = average systolic blood pressure, BMI = body mass index, BP = blood pressure, BPV = blood pressure variability, CGN = chronic glomerulonephritis, CI = confidence intervals, CKD = chronic kidney disease, CV = coefficient of variation, DBP = diastolic blood pressure, DKD = diabetic kidney disease, DN = diabetic nephropathy, ESRD = end-stage renal disease, HR = hazard ratio, iPTH = parathyroid hormone, KDIGO = Kidney Disease: Improving Global Outcomes, LDL-C = low-density lipoprotein-cholesterol, SBP = systolic blood pressure, SD = standard deviation, TC = total cholesterol, TG = triglyceride, VIM = variability independent of mean.

Keywords: blood pressure variability, diastolic blood pressure, hemodialysis, stroke, systolic blood pressure

1. Introduction
Hypertension is highly prevalent in hemodialysis patients, and it is often poorly controlled.\cite{1,2} Several studies have indicated that hypertension is associated with an increased risk for stroke.\cite{3,4} In a recent series of articles, Rothwell et al reported that blood pressure (BP) variability (BPV) is a risk factor for stroke, independent of the mean BP, among high-risk patients, suggesting that the visit-to-visit variability in BP may have an important additional role in increasing the risk for vascular events, particularly for stroke.\cite{5,6} To our knowledge, the influence of BP vBPV on the risk for stroke in the end-stage renal disease (ESRD) population has not been widely studied, especially in hemodialysis patients. Moreover, previous studies in hemodialysis patients focused more on the impact of short-term BPV on prognosis;\cite{7–11} the effects of long-term BPV are less well-investigated.\cite{12–14} Therefore, we planned to examine the association between long-term BPV and the occurrence of stroke in patients with maintenance hemodialysis.

The optimum method for evaluating BPV for hemodialysis patients is unclear. Previous studies have suggested that visit-to-visit pre-dialysis BPV is associated with mortality among hemodialysis patients.\cite{12,15,16} However, these studies are limited by short duration of follow-up\cite{12,16} and use of measures of BPV that are associated with mean BP levels.\cite{16} Therefore, more comprehensive and objective metrics were used to define BPV in this study. Moreover, differences in the predialysis BPs from one
treatment to the next (ie, interdialytic variability) and differences in the BPs from predialysis to post-dialysis (ie, intradialytic variability) were both studied in this work because factors such as rapid fluid removal through ultrafiltration, abrupt changes in serum osmolarity, acid-base composition, and electrolyte composition may lead to BP fluctuation.

2. Patients and methods

2.1. Patients

Patients aged 18 to 75 years with ESRD who were undergoing maintenance hemodialysis for at least 3 months in the Department of Nephrology in the General Hospital of Western Theater Command were included in the study. The exclusion criteria included a previous stroke before undergoing maintenance hemodialysis. Furthermore, patients with systemic vasculitis, polycystic kidney disease, malignancy, and other autoimmune diseases were excluded to avoid the possible effects of these comorbid conditions on the vascular condition of these patients. Between July 2012 and November 2012, a total of 151 patients were enrolled in this study. A prospective study was performed on this group of hemodialysis patients. Baseline demographic indexes were recorded at the time of entry into the study. The type of vascular access, whether complicated with atrial fibrillation, and the use of anti-hypertensive drugs, anti-platelet drugs, and statins were recorded. The patients were followed for 48 months or until stroke or death occurred.

All of the patients received 4 hours of conventional hemodialysis with a bicarbonate bath 3 times weekly (GAMBRO, polyflux 17R, Germany). The blood flow rates ranged from 200 to 300 mL/min, with a fixed dialysate flow rate of 500 mL/min. The dialysate composition was as follows: Na+ 135 to 145 mmol/L, K + 2.0 mmol/L, and Ca++ 1.5 mmol/L. Low-molecular-weight heparin was used routinely during the dialysis. Antihypertensive drugs (angiotensin-converting enzyme inhibitors, calcium channel blockers, β blockers, and so on) were prescribed if hypertension persisted despite the patient’s volume status being well controlled. Dialysis-related variables including dialysis vintage, ultrafiltration rate, equilibrated Kt/V, and average dose of low molecular heparin were collected.

The study protocol was approved by the local Ethics Committee, and all of the patients provided written informed consent.

2.2. Laboratory methods

Blood samples were drawn every 3 months after enrolment. The blood was taken at the interval day of dialysis. The numbers of white blood cells, platelet count, and serum levels of hemoglobins, albumin, creatinine, phosphate, calcium, nitrogen, low-density lipoprotein-cholesterol (LDL-C), triglyceride, total cholesterol, and intact parathyroid hormone (iPTH) were measured using automated and standardized methods at a centralized laboratory. All of the clinical data referenced above are expressed as the means with standard deviation (SD).

2.3. BP measurements and definitions of BPV

At each routine hemodialysis visit, BP measurements were performed by trained nurses in the right or left arm of the patient, who was in a supine body position, using a mercury sphygmomanometer with an appropriate cuff. Predialysis, intradialytic (after 2 hours of dialysis), and post-dialysis measurements were systematically performed. The visit-to-visit BPV was quantified by 4 metrics: the SD of the BP, the coefficient of variation (CV = SD/mean × 100%), the average real variability (ARV), which takes an average of the absolute differences in BP over consecutive visits, and variability independent of mean (VIM). VIM is the proportional to SD/mean, with x derived from curve fitting.

To distinguish between the BPV during the dialysis period and the BPV in the dialysis interphase, the SD, CV, ARV, and VIM of the predialysis BP was used to represent the BPV in the dialysis interphase, whereas the residual visit-to-visit variability of BP (residual visit-to-visit variability of BP = total variance of all BP – between-individual variance in mean BP – between-individual variance in within-individual visit-to-visit BP) was used to represent the BPV during the dialysis period.

2.4. Stroke events

Newly developed cerebrovascular disease was diagnosed by both clinical symptoms and brain imaging examination (computed tomography or magnetic resonance imaging scan).

2.5. Statistical analysis

The data are expressed either as the means with SD or as number of patients (percentage), and 95% confidence intervals (CIs) are provided where appropriate. Differences in continuous values between 2 groups were assessed with the independent-samples t test. Associations between the outcome of stroke and the categorical factors were determined by the Kaplan–Meier method. The survival curves were estimated using the Kaplan–Meier method, and differences in the survival rate distributions were evaluated by the log-rank test. A multivariate analysis of survival was performed using a Cox proportional hazards regression model. The age, sex, and the factors that met the significance criterion (univariate analysis, P < .05) were considered for inclusion in an initial model (Model 1). Model 2 included covariates in Model 1 plus the mean BP. All of the tests were 2-sided, and differences were considered significant at P < .05. All of the statistical analyses were performed using SPSS software, version 16.

3. Results

3.1. Patient characteristics and laboratory data

A total of 151 patients were enrolled in this study. Twenty-one patients developed stroke (ischemic stroke occurred in 11 patients, hemorrhagic stroke occurred in 5 patients, subarachnoid hemorrhage occurred in 2 patients, and another 3 patients developed intracranial hemorrhage) and 25 patients died (10 patients died due to cardiovascular events, 8 patients died due to stroke, 2 patients died due to upper gastrointestinal bleeding, 4 patients died due to serious infection, and 1 patient died due to acute severe pancreatitis). The baseline characteristics and laboratory indexes of the study population are summarized in Table 1. The average age of the patients was 51.95 ± 15.26 years, and the patients’ average dialysis vintage was 5.60 ± 3.69 years. The description of BPV is
summarized in Table 2. The SD, CV, ARV, and VIM of both the predialysis systolic BP (SBP) and predialysis diastolic BP (DBP) were displayed. The BPV during the dialysis period was also displayed.

3.2. Univariate analysis

The Kaplan–Meier analysis showed that age, albumin level, dialysis vintage, LDL-C level, atrial fibrillation, anti-platelet therapy, and statins were correlated with increased/decreased incidence of stroke (Table 3, Log-rank test: P < .05). A higher predialysis SBP variability (calculated using SD, CV, ARV, and VIM) was significantly associated with higher rates of stroke (Table 3, Log-rank test: P < .05). A higher predialysis DBP variability (calculated using SD, CV, and VIM) was also related to stroke (Table 3, Log-rank test: P < .05). The results showed that the serum levels of high-sensitive C-reactive protein, homocysteine, cholesterol, calcium, phosphorus, and iPTH were not related to stroke (data shown in Supplemental Digital Content [Table 1 Appendix, http://links.lww.com/MD/E525]). Additionally, the hemoglobin and platelet count values were also not related to stroke (data shown in Supplemental Digital Content [Table 1 Appendix, http://links.lww.com/MD/E525]).

### Table 1
Demographics and clinical characteristics of the study population (n = 151).

|                      | N (%)       | Mean ± SD    |
|----------------------|-------------|--------------|
| Sex                  |             |              |
| Female               | 69 (45.70)  |              |
| Male                 | 82 (54.30)  |              |
| Age, y               |             |              |
| <60                  | 107 (70.86) |              |
| ≥60                  | 44 (29.14)  |              |
| Hemoglobin, g/L      |             |              |
| <90                  | 9 (5.96)    |              |
| ≥90                  | 38 (25.17)  |              |
| ≥105                 | 91 (60.26)  |              |
| ≥120                 | 13 (8.61)   |              |
| Platelets (>×10^9 cells/L) | 139.32 ± 44.64 |
| Platelets group (>×10^9 cells/L) | 78 (51.66)  |
| Albumin, g/L         |             | 39.46 ± 2.98 |
| Albumin group, g/L   |             | 86 (56.95)   |
| ≥35                  | 65 (43.05)  |              |
| LDL-C, mmol/L        |             | 2.02 ± 0.59  |
| LDL-C group, mmol/L  |             | 78 (51.66)   |
| ≥2.02                | 73 (48.34)  |              |
| Total cholesterol, mmol/L | 3.76 ± 0.74  |
| Total cholesterol group, mmol/L | 82 (54.30)  |
| Calcium, mmol/L      |             | 2.27 ± 0.18  |
| Calcium group, mmol/L|             | 11 (7.28)    |
| ≥2.0                 | 120 (85.43) |              |
| ≥2.5                 | 11 (7.28)   |              |
| Phosphorus, mmol/L   |             | 1.81 ± 0.44  |
| Phosphorus group, mmol/L | 75 (49.67)  |
| ≥1.78                | 76 (50.33)  |              |
| Intact parathyroid hormone, pg/mL | 367.33 ± 405.06 |
| Intact parathyroid hormone group, pg/mL | 44 (29.14)  |
| ≥150                 | 53 (35.10)  |              |
| ≥300                 | 30 (19.87)  |              |
| ≥600                 | 24 (15.89)  |              |
| Diabetes mellitus    |             |              |
| No                   | 129 (85.43) |              |
| Yes                  | 22 (14.57)  |              |
| Smoke                |             |              |
| Never                | 76 (50.33)  |              |
| Ever                 | 75 (49.67)  |              |
| Dialysis vintage, y  |             | 5.60 ± 3.69  |
| Dialysis vintage group, y | 89 (58.94)  |
| ≥5.60                | 62 (41.06)  |              |
| Average dose of low molecular heparin, U | 3596.00 ± 730.00 |
| Average dose of low molecular heparin group, U | 13 (8.61)    |
| ≥2000                | 38 (25.17)  |              |
| ≥3000                | 100 (66.23) |              |
| Antihypertensive drug types |            |
| ≤1                   | 26 (17.22)  |              |
| 2                    | 73 (48.34)  |              |
| 3                    | 52 (34.44)  |              |
| BMI, kg/m²           |             | 22.07 ± 3.82 |
| BMI group, kg/m²     |             | 28 (18.54)   |
| <18.5                | 79 (52.32)  |              |
| ≥24.0                | 44 (29.14)  |              |
| Kt/V                 |             | 1.41 ± 0.14  |
| Kt/V group           |             | 89 (58.94)   |
| ≤1.41                | 62 (41.06)  |              |
| Ultrafiltration ratio (%) | 3.84 ± 1.14  |
| Ultrafiltration ratio group | 32 (21.19)  |
| ≥3                   | 98 (64.90)  |              |

(continued)
3.3. Multivariate analysis

Multivariate Cox proportional hazards model was performed to assess the independent association of each parameter with the rates of stroke. An initial model (Model 1) provided hazard ratio (HR) for stroke with BPV, adjusting for sex, age, albumin level, dialysis vintage, LDL-C level, atrial fibrillation, antiplatelet therapy, and statins (Table 4). Model 2 included covariates in Model 1 plus the average BP (Table 4). Cox proportional hazards multivariate analysis revealed a significant relationship between the stroke outcome and the predialysis SBP variability calculated using SD (HR 3.110, P = .032, Model 1), ARV (HR 2.600, P = .040, Model 1), and VIM (HR 5.184, P = .005, Model 1). Similar results were observed in Model 2, when variability of SBP was calculated using SD, ARV, and VIM. Moreover, after

### Table 2

**Description of BPV.**

|                      | Mean ± SD | Median (P25, P75) | Min, Max |
|----------------------|-----------|-------------------|----------|
| Pre-dialysis SBP variability |           |                   |          |
| SD                   | 10.94 ± 3.05 | 10.89 (8.75, 12.99) | 3.05, 18.27 |
| CV (%)               | 7.80 ± 1.91  | 7.73 (6.42, 9.28)  | 2.33, 12.22 |
| ARV                  | 47.87 ± 15.92 | 50 (40, 60)       | 20, 100 |
| VIM (×10^5)          | 2.59 ± 0.64  | 2.5 (2.18, 2.95)  | 0.89, 5.38 |
| Predialysis DBP variability |         |                   |          |
| SD                   | 7.03 ± 1.59   | 6.97 (5.99, 7.76)  | 3.75, 15.91 |
| CV (%)               | 6.23 ± 1.86   | 7.68 (7.04, 9.07)  | 4.22, 19.12 |
| ARV                  | 30.95 ± 11.13 | 30 (20, 38)       | 10, 120  |
| VIM (×10^5)          | 1.23 ± 0.28   | 1.18 (1.06, 1.39)  | 0.64, 2.86 |
| SBP residual visit-to-visit variability | 41.31 ± 26.49 | 36.5 (22.35, 50.15) | 7.42, 174.28 |
| DBP residual visit-to-visit variability | 20.56 ± 17.57 | 27.35 (15.27, 40.51) | 1.90, 83.85 |

ARV = average real variability, CV = coefficient of variation, DBP = diastolic blood pressure, LDL-C = low density lipoprotein cholesterol, SBP = systolic blood pressure, SD = standard deviation, VIM = variability independent of mean.

### Table 3

**Univariate analysis of factors influencing stroke.**

| Stroke                          | Unvaried, n = 130 | Yes, n = 21 | Mean of the survival time, mo (mean ± SE) | χ^2* | P |
|---------------------------------|-------------------|-------------|------------------------------------------|------|---|
| Age group, y                    |                   |             |                                          |      |   |
| <60                             | 96 (89.72)        | 11 (10.28)  | 45.10 ± 0.92                             | 5.176| .023|
| ≥60                             | 34 (77.27)        | 10 (22.73)  | 42.02 ± 1.82                             |      |   |
| Albumin group, g/L              |                   |             |                                          |      |   |
| <35                             | 70 (81.40)        | 16 (18.60)  | 43.21 ± 1.21                             | 3.879| .049|
| ≥35                             | 60 (92.31)        | 5 (7.69)    | 45.61 ± 1.11                             |      |   |
| LDL-C group, mmol/L             |                   |             |                                          |      |   |
| <2.02                           | 72 (92.31)        | 6 (7.69)    | 46.17 ± 0.80                             | 5.034| .025|
| ≥2.02                           | 56 (79.45)        | 15 (20.55)  | 42.26 ± 1.46                             |      |   |
| Dialysis vintage group, y       |                   |             |                                          |      |   |
| <5.60                           | 72 (90.90)        | 17 (19.10)  | 42.70 ± 1.31                             | 4.857| .028|
| ≥5.60                           | 58 (93.55)        | 4 (6.45)    | 46.52 ± 0.76                             |      |   |
| Atrial fibrillation             |                   |             |                                          |      |   |
| No                              | 123 (87.86)       | 17 (12.14)  | 44.74 ± 0.83                             | 6.503| .011|
| Yes                             | 7 (83.64)         | 4 (16.36)   | 37.83 ± 4.31                             |      |   |
| Antiplatelet drugs              |                   |             |                                          |      |   |
| No                              | 123 (87.86)       | 17 (12.14)  | 44.74 ± 0.83                             | 6.503| .011|
| Yes                             | 7 (83.64)         | 4 (16.36)   | 37.83 ± 4.31                             |      |   |
| Statins                         |                   |             |                                          |      |   |
| No                              | 127 (86.99)       | 19 (13.01)  | 44.54 ± 0.83                             | 4.547| .033|
| Yes                             | 5 (60.00)         | 2 (40.00)   | 35.55 ± 7.27                             |      |   |
| Predialysis SBP-SD group        |                   |             |                                          |      |   |
| <Median                         | 71 (93.42)        | 5 (6.58)    | 45.94 ± 0.96                             | 6.494| .011|
| ≥Median                         | 59 (78.67)        | 16 (21.33)  | 42.60 ± 1.36                             |      |   |
| Predialysis SBP-CV group (%)    |                   |             |                                          |      |   |
| <Median                         | 70 (92.11)        | 6 (7.90)    | 45.49 ± 1.05                             | 4.518| .034|
| ≥Median                         | 60 (80.00)        | 15 (20.00)  | 43.02 ± 1.31                             |      |   |
| Predialysis SBP-ARV group       |                   |             |                                          |      |   |
| <Median                         | 96 (90.57)        | 10 (9.43)   | 45.58 ± 0.82                             | 6.655| .010|
| ≥Median                         | 34 (75.56)        | 11 (24.44)  | 41.16 ± 2.00                             |      |   |
| Predialysis SBP-VIM group (×10^5) |           |             |                                          |      |   |
| <Median                         | 72 (94.74)        | 4 (5.26)    | 46.37 ± 0.83                             | 9.751| .002|
| ≥Median                         | 58 (77.33)        | 17 (22.67)  | 42.09 ± 1.44                             |      |   |
| Predialysis DBP-SD group        |                   |             |                                          |      |   |
| <Median                         | 71 (93.42)        | 5 (6.58)    | 46.07 ± 0.87                             | 7.000| .008|
| ≥Median                         | 59 (78.67)        | 16 (21.33)  | 42.41 ± 1.42                             |      |   |
| Predialysis DBP-CV group (%)    |                   |             |                                          |      |   |
| <Median                         | 69 (92.00)        | 6 (8.00)    | 45.54 ± 1.00                             | 4.462| .035|
| ≥Median                         | 61 (80.26)        | 15 (19.74)  | 42.98 ± 1.34                             |      |   |
| Predialysis DBP-VIM group (×10^5) |           |             |                                          |      |   |
| <Median                         | 70 (92.11)        | 6 (7.89)    | 45.57 ± 0.99                             | 4.766| .029|
| ≥Median                         | 60 (80.00)        | 15 (20.00)  | 42.91 ± 1.35                             |      |   |

χ^2* Kaplan–Meier method, Log–rank test statistics.

ARV = average real variability, CV = coefficient of variation, DBP = diastolic blood pressure, LDL-C = low density lipoprotein cholesterol, SBP = systolic blood pressure, SD = standard deviation, VIM = variability independent of mean.
adjustment for the average predialysis SBP, CV was significantly associated with the incidence of stroke (HR 3.358, P = .024, Model 2). The associations between variability of predialysis DBP and the risk of stroke were also calculated. In Model 1, stroke was detected to be significantly associated with SD of DBP (HR 4.589, P = .004, Model 1), CV of DBP (HR 3.226, P = .019, Model 1), and VIM of DBP (HR 3.537, P = .011, Model 1). Similar results were also observed when adjusted by the average predialysis DBP. In addition, dialysis vintage was observed to be significantly associated with the rates of stroke. The patients with relatively short dialysis vintage (<5.6 years) were more prone to stroke. Results also showed that high levels of LDL-C were associated with stroke (data shown in Supplemental Digital Content [Table 2 Appendix, http://links.lww.com/MED/ES26]).

4. Discussion

Numerous studies on nondialysis populations have linked visit-to-visit BPV to cerebrovascular events and mortality.\(^{[5,6,22,23]}\) A recent study demonstrated an association between the visit-to-visit BPV and mortality in a chronic kidney disease (CKD) population, supporting the notion that BP fluctuation may be particularly detrimental to patients with decreased kidney function.\(^{[24]}\) As we know, ESRD is associated with an increased risk for stroke.\(^{[25]}\) BPV is potentially of an even greater significance among hemodialysis patients than among other populations. In this study, the link between the visit-to-visit BPV and stroke in hemodialysis patients was observed. Evidence from recent studies suggests that the visit-to-visit variability over longer periods of follow-up may have a greater prognostic value than the mean BP or the short-term variability.\(^{[22]}\) Therefore, the patients in this study were followed for 48 months until stroke or death occurred.

As for the influence of factors such as the rapid fluid removal through ultrafiltration, which leads to abrupt changes in the serum osmolarity, acid-base composition, and electrolyte composition, the activation of neurohormonal axes, and the diacytic removal of vasoactive medications, the intradialytic and interdialytic BP were distinguishable in our study.\(^{[17]}\) The intradialytic BPV expresses the fluctuation of the BP from predialysis to post-dialysis, and the inter-dialytic BPV expresses the difference in the predialysis BP from one treatment to the next. To better describe and quantify the BPV, we considered 4 metrics of the BPV including SD, CV, ARV, and VIM, which is a transformation of the SD that is uncorrelated with mean BP.

During hemodialysis, patients are routinely exposed to rapid fluid and osmolarity shifts that result in BP fluctuation. Nevertheless, an association between the intradialytic BPV and stroke was not observed in this study. There is potential that the fine interdialytic weight control (the mean dehydration ratio was 3.84% ± 1.14%) helped lower the BP fluctuation in these patients, which possibly weakened the relationship between the intradialytic BPV and stroke.

Our analysis shows that a high predialysis SBP variability is associated with a higher risk for stroke. The findings from our study are consistent with a few previous studies conducted in hemodialysis patients showing that higher predialysis SBP variability is independently associated with a higher risk for adverse outcomes. For example, an observational study of 1088 prevalent patients on hemodialysis in Italy showed that higher predialysis SBP variability was associated with a significantly higher risk of cardiovascular mortality.\(^{[26]}\) Similarly, another randomized trial comparing fosinopril to placebo in patients on hemodialysis with left ventricular hypertrophy\(^{[20]}\) demonstrated an increased risk of the composite outcome of cardiovascular events or cardiovascular death associated with higher predialysis SBP CV. Most previous studies on the BPV and outcomes focused on the SBP variability,\(^{[5,23,27,28]}\) and relatively little is known about the relationship between the DBP variability and stroke. Our results indicate that a high predialysis DBP variability is associated with an increased risk for stroke that is independent of several factors, including age, sex, antihypertensive medication use, and mean BP over time. These findings have implications for clinical practice. The interdialytic BPV (not only predialysis SBP variability but also predialysis DBP variability) might be more closely correlated with the stroke outcome than either the mean BP or the intradialytic BPV, although the reasons for this are unknown. The optimal treatment goal for hemodialysis patients may be to reduce the interdialytic BPV rather than the mean BP values. The putative factors that explain the link between the interdialytic BPV and stroke are unclear. Atherosclerosis, angiostenosis, increased wall stress, baroreceptor dysfunction, and endothelial dysfunction are possible mechanisms.\(^{[29–31]}\) Furthermore, our results indicated that the level of LDL-C was associated with stroke, which has been identified in several previous studies on different populations.\(^{[32,33]}\)

The Kidney Disease: Improving Global Outcomes clinical practice guidelines have suggested that statins or a statin/ezetimibe combination should not be initiated in adults with dialysis-dependent CKD.\(^{[34]}\)

### Table 4

|                           | Model 1 |                  | P    | Model 2 |                  | P    |
|---------------------------|---------|------------------|------|---------|------------------|------|
| Predialysis SBP variability |         |                  |      |         |                  |      |
| SD (≥median VS < median)  | 3.110   | 1.102, 8.776     | .032 | 4.875   | 1.619, 14.675    | .005 |
| CV (≥median VS < median)  | 2.392   | 0.889, 6.434     | .084 | 3.358   | 1.173, 9.611     | .024 |
| ARV (≥median VS < median) | 2.600   | 1.045, 6.407     | .040 | 3.893   | 1.381, 10.973    | .010 |
| VM (≥median VS < median)  | 5.184   | 1.647, 16.321    | .005 | 5.225   | 1.656, 16.484    | .005 |
| Predialysis DBP variability |         |                  |      |         |                  |      |
| SD (≥median VS < median)  | 4.589   | 1.609, 13.088    | .004 | 5.328   | 1.852, 15.331    | .002 |
| CV (≥median VS < median)  | 3.226   | 1.213, 8.583     | .019 | 3.148   | 1.733, 8.449     | .023 |
| VM (≥median VS < median)  | 3.537   | 1.542, 9.323     | .011 | 3.521   | 1.329, 9.326     | .011 |

Model 1: adjusted by sex, age, albumin level, dialysis vintage, LDL-C level, atrial fibrillation, anti-platelet therapy, and statins.

Model 2: adjusted by sex, age, albumin level, dialysis vintage, LDL-C level, atrial fibrillation, anti-platelet therapy, statins, and the pre-dialysis average BP.

ARV = average real variability, CI = confidence interval, CV = coefficient of variation, DBP = diastolic blood pressure, HR = hazard ratio, SBP = systolic blood pressure, SD = standard deviation, VM = variability independent of mean.
Whether there are any other methods that could be adopted to decrease the stroke risk in hemodialysis patients with a high LDL-C level needs to be studied further.

Interestingly, we found that patients with shorter dialysis vintage (<5.6 years) were more likely to have stroke in this study. Detailed analysis showed that the mean BP of patients with shorter dialysis vintage (<5.6 years) was higher than that in patients with longer dialysis vintage (≥5.6 years) (Table 5). This was probably the reason for the increased risk of stroke in patients with shorter dialysis vintage. There might be survivor bias in individual cases. For example, the only patients who would survive that long on hemodialysis were exceptionally healthy, with better cardiovascular health. However, other possible reasons need further study.

There are some limitations of the present study that need to be addressed. The study was performed in a single hospital, and thus, the sample size was not large enough, and there was a lack of baseline radiographic data from the patients. Considering the small sample size of this study, when analyzing the relationship between the BPV and the outcome of stroke, we did not differentiate between ischemic stroke and hemorrhagic stroke. Further studies using a larger patient cohort and involving several centers are needed to provide insight into the mechanistic link between the inter-dialytic BPV and different types of stroke.

Author contributions

Conceptualization: Jun Zhu, Tao Wang.
Data curation: Yuming Li.
Investigation: Meng Wei, Liwen Mo, Yi Li.
Methodology: Fan Zhang.
Validation: Yuming Li.
Writing – original draft: Yue Cheng.
Writing – review & editing: Tao Wang.

References

[1] Bakris GL, Burkart JM, Weinhandl ED, et al. Intensive hemodialysis, blood pressure, and antihypertensive medication use. Am J Kidney Dis 2014;63(5):523.
[2] Holr MP, Holr WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002;39:227–44.
[3] Dakay K, Silver B. Blood pressure and prevention of stroke. Semin Neurol 2017;37:274–85.
[4] Murakami K, Asayama K, Satoh M, et al. Home blood pressure predicts stroke incidence among older adults with impaired physical function: the Ohasama study. J Hypertens 2017;10:1097.
[5] Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:995–905.
[6] Dai H, Lu Y, Song L, et al. Visit-to-visit variability of blood pressure and risk of stroke: results of the Kailuan cohort study. Sci Rep 2017;7:285.
[7] Errukk S, Erruk AE, Ates K, et al. Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in hemodialysis patients. Nephrol Dial Transplant 1996;11:2050–4.
[8] Goldsmith DJ, Covic AC, Venning MC, et al. Ambulatory blood pressure monitoring in renal dialysis and transplant patients. Am J Kidney Dis 1997;29:593–600.
[9] Liu M, Takahashi H, Morita Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in hemodialysis patients. Nephrol Dial Transplant 2003;18:563–9.
[10] Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009;207:186–90.
[11] Trpevi G, Fagugi RM, Dattolo P, et al. Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int 2005;68:1294–302.
[12] Brunelli SM, Thadhani RI, Lynch KE, et al. Association between long-term blood pressure variability and mortality among incident hemodialysis patients. Am J Kidney Dis 2008;52:716–26.
[13] Selvarajah V, Pasea L, Ojha S, et al. Pre-dialysis systolic blood pressure variability is independently associated with all-cause mortality in incident hemodialysis patients. PLoS One 2014;9:e86514.
[14] Tozawa M, Iseki K, Yoshi S, et al. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 1999;14:796–81.
[15] Chang TI, Flythe JE, Brunelli SM, et al. Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. J Hum Hypertens 2013;1:7. doi:10.3383/jhh.2013.49.
[16] Tozawa M, Iseki K, Yoshi S, et al. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrology Dialysis Transplantation 1999;14:796–81.
[17] Flythe JE, Kunnaparaj S, Dinesh K, et al. Factors associated with intradialytic systolic blood pressure variability. Am J Kidney Dis 2012;59:409–18.
[18] Chen H, Zhang R, Zheng Q, et al. Impact of body mass index on long-term blood pressure variability: a cross-sectional study in a cohort of Chinese adults. BMC Public Health 2019;19:1193–200.
[19] Chua YC, Lim HM, Ching SM. Long-term visit-to-visit blood pressure variability and renal function decline in patients with hypertension over 15 years. J Am Heart Assoc 2016;5:e003825.
[20] Rossignol P, Gridlig J, Lehert P, et al. Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension 2012;60:339–46.

[21] Peter MR, Sally CH, Eamon D, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic. Hypertension Lancet 2010;375:893–905.

[22] Gosmanova EO, Mikkelsen MK, Molnar MZ, et al. Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease. J Am Coll Cardiol 2016;68:1375–86.

[23] Suchy-Dicey AM, Wallace ER, Mitchell SV, et al. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. Am J Hypertens 2015;26:1210–7.

[24] Chang TI, Tabada GH, Yang J, et al. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J Hypertens 2016;34:244–52.

[25] Cherian L, Conners J, Cutting S, et al. Peri-procedural risk of stroke is elevated in patients with end-stage renal disease on hemodialysis. Cerebrovasc Dis Extra 2015;5:91–4.

[26] Di Iorio B, Di Micco L, Torraca S, et al. Variability of blood pressure in dialysis patients: a new marker of cardiovascular risk. J Nephrol 2013;26:173–82.

[27] Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women’s Health Initiative. Hypertension 2012;60:625–30.

[28] Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011;57:160–6.

[29] Ye F, Yu NW, Wu WB, et al. Impact of awake blood pressure variability on cerebrovascular atherosclerosis in Chinese patients with acute ischemic stroke. Blood Press Monit 2016;21:271–6.

[30] Smirl JD, Haykowsky MJ, Nelson MD, et al. Relationship between cerebral blood flow and blood pressure in long-term heart transplant recipients. Hypertension 2014;64:1314–20.

[31] Tedla YG, Yano Y, Carnethon M, et al. Association between long-term blood pressure variability and 10-year progression in arterial stiffness: the multiethnic study of atherosclerosis. Hypertension 2017;69:118–27.

[32] Sanossian N, Tarlov NE. HDL-C and LDL-C. Their role in stroke pathogenesis and implications for treatment. Curr Treat Options Cardiovasc Med 2008;10:195–206.

[33] Zeljkovic A, Vekic J, Spasojevic-Kahmanovska V, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010;210:548–54.

[34] KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney International Supplements 2013;3:271–9.